Nanobiotix SA NANO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
-
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
-
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Voting Rights and Shares Capital of the Company
-
Voting Rights and Shares Capital of the Company
Trading Information
- Previous Close Price
- €4.67
- Day Range
- €4.65–5.13
- 52-Week Range
- €3.82–9.30
- Bid/Ask
- €4.94 / €5.07
- Market Cap
- €235.60 Mil
- Volume/Avg
- 135,282 / 52,856
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 110
- Website
- https://www.nanobiotix.com
Comparables
Valuation
|
Metric
|
NANO
|
ALCLS
|
IPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.41 | 5.65 |
Price/Sales | 5.54 | 11.47 | 6.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
NANO
ALCLS
IPH
Financial Strength
|
Metric
|
NANO
|
ALCLS
|
IPH
|
|---|---|---|---|
Quick Ratio | 1.38 | 1.87 | 2.76 |
Current Ratio | 1.42 | 1.92 | 2.92 |
Interest Coverage | −3.42 | −15.16 | −20.73 |
Quick Ratio
NANO
ALCLS
IPH
Profitability
|
Metric
|
NANO
|
ALCLS
|
IPH
|
|---|---|---|---|
Return on Assets (Normalized) | −41.57% | −34.94% | −17.56% |
Return on Equity (Normalized) | — | −107.90% | −67.77% |
Return on Invested Capital (Normalized) | −103.38% | −57.16% | −39.20% |
Return on Assets
NANO
ALCLS
IPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Prwkrbvlg | Zmy | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wglwyggc | Dmlbxv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pwdpccjkn | Fvlyz | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Csmjrdsc | Nwfcf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Lkmjrqyz | Dzkq | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Szdnhdqn | Pny | $28.1 Bil | |||
| Moderna Inc
MRNA
| Jmhsgxs | Hvxx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fmfczbpsh | Glxz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fvtnbyyk | Sdxtbsp | $13.4 Bil | |||
| Incyte Corp
INCY
| Ctmbxlpw | Wtdhk | $12.7 Bil |
United States